Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW-Smk-1: Brenipatide to reduce relapse to cigarette smoking
jRCT2031250568Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2025
- Modality
- Peptides
01
Overview
Phase 2, randomised, double-blind trial in nicotine dependence comparing Brenipatide with Placebo (2 arms). Primary endpoint: Percentage of participants with CO-confirmed continuous abstinence with allowed slips. Started Dec 2025; status: recruiting.
02
Drugs
brenipatide
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on jRCT2031250568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250568.